Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease

Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD patients. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Huoponen, Saara, Eberl, Anja, Räsänen, Pirjo, Roine, Risto P., Sipponen, Taina, Arkkila, Perttu, Blom, Marja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959900/
https://www.ncbi.nlm.nih.gov/pubmed/31914087
http://dx.doi.org/10.1097/MD.0000000000018723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959900/
https://www.ncbi.nlm.nih.gov/pubmed/31914087
http://dx.doi.org/10.1097/MD.0000000000018723

Ejemplares similares